<p>TuHURA Biosciences（纳斯达克：HURA - 获取免费报告）预计将在 5 月 15 日（星期五）公布其业绩。分析师预计该公司本季度每股收益为（$0.12）。</p>
<p>获取 <strong>TuHURA Biosciences</strong> 的提醒：</p>
<p>TuHURA Biosciences（纳斯达克：HURA - 获取免费报告）最近一次发布季度财报是在 3 月 31 日（星期二）。该公司报告本季度每股收益为（$0.13），低于市场共识预期的（$0.12），差距为（$0.01）。分析师平均预计 TuHURA Biosciences 在当前财年每股收益为$0，在下一个财年每股收益也为$0。</p>
<h2>TuHURA Biosciences 股价下跌 5.5%</h2>
<p>TuHURA Biosciences 的股票在星期五开盘价为$2.40。该公司的市值为 1.5283 亿美元，市盈率为-3.81，贝塔值为-0.01。TuHURA Biosciences 的 12 个月低点为$0.41，12 个月高点为$4.20。该股票的 50 日移动平均线为$2.05，200 日移动平均线为$1.60。</p>
<h2>分析师设定新目标价</h2>
<p>一些股票研究分析师最近对 HURA 股票发表了看法。Weiss Ratings 在 4 月 21 日（星期二）发布的报告中重新给予 TuHURA Biosciences 股票&#34;卖出（e+）&#34;评级。花旗集团在 4 月 27 日（星期一）的研究报告中开始覆盖 TuHURA Biosciences 股票，并给予&#34;跑赢大盘&#34;评级。Citizens Jmp 在 4 月 27 日（星期一）的研究报告中开始覆盖 TuHURA Biosciences 股票，并给予&#34;市场跑赢&#34;评级，目标价为$9.00。HC Wainwright 在 2 月 3 日（星期二）重新给予&#34;买入&#34;评级，并设定目标价为$10.00。最后，Rodman &amp; Renshaw 在 4 月 15 日（星期三）的研究报告中开始覆盖 TuHURA Biosciences 股票，并给予&#34;买入&#34;评级。五位投资分析师对该股票给予买入评级，一位分析师给予卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为&#34;适度买入&#34;，平均目标价为$9.00。</p>
<p><strong>查看我们对 TuHURA Biosciences 的最新分析</strong></p>
<h2>对 TuHURA Biosciences 的对冲基金看法</h2>
<p>几家机构投资者和对冲基金最近增加或减少了对该公司的持股。Virtu Financial LLC 在第三季度购买了 TuHURA Biosciences 的新股份，价值$26,000。摩根大通在第二季度购买了 TuHURA Biosciences 的新头寸，价值$27,000。Invesco Ltd.在第二季度购买了 TuHURA Biosciences 的新头寸，价值约$30,000。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第二季度收购了 TuHURA Biosciences 的新股份，价值$31,000。最后，美国银行在第四季度购买了 TuHURA Biosciences 的新头寸，价值$59,000。目前，机构投资者和对冲基金持有该股票的 0.62%。</p>
<h2>TuHURA Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>TuHURA Biosciences 是一家临床阶段的生物技术公司，专注于利用高维蛋白质组学发现和开发新型治疗药物。公司的核心使命是将复杂的蛋白质特征转化为可操作的药物靶点，涵盖多种疾病领域。通过将蛋白质组数据与先进的计算分析相结合，TuHURA 旨在弥合分子疾病理解与首创疗法开发之间的差距。</p>
<p>TuHURA 的方法的核心是其专有平台，该平台利用多重蛋白质分析生成丰富的疾病状态表型图。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 TuHURA Biosciences</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVSQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 TuHURA Biosciences 吗？</h2>
<p>在你考虑 TuHURA Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 TuHURA Biosciences 并不在名单上。</p>
<p>虽然 TuHURA Biosciences 目前在分析师中获得&#34;适度买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HURA

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>TuHURA Biosciences (NASDAQ:HURA) 将于 5 月 15 日（星期五）公布其财报，分析师预计每股亏损 0.12 美元。该公司之前报告的每股亏损为 0.13 美元，未能达到预期。目前，TuHURA 的股票交易价格为 2.40 美元，下跌 5.5%，市值为 1.5283 亿美元。分析师的评级意见不一，普遍共识为 “适度买入”，平均目标价格为 9.00 美元。机构投资者最近增加了对该公司的持股，该公司专注于通过蛋白质组学开发新型治疗药物</p>

<p>TuHURA Biosciences (NASDAQ:HURA - Get Free Report) is projected to announce its resultson Friday, May 15th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.</p>
<div class="lb-trans"><p>TuHURA Biosciences（纳斯达克：HURA - 获取免费报告）预计将在 5 月 15 日（星期五）公布其业绩。分析师预计该公司本季度每股收益为（$0.12）。</p>
</div><p>Get <strong>TuHURA Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>TuHURA Biosciences</strong> 的提醒：</p>
</div><p>TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). On average, analysts expect TuHURA Biosciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>TuHURA Biosciences（纳斯达克：HURA - 获取免费报告）最近一次发布季度财报是在 3 月 31 日（星期二）。该公司报告本季度每股收益为（$0.13），低于市场共识预期的（$0.12），差距为（$0.01）。分析师平均预计 TuHURA Biosciences 在当前财年每股收益为$0，在下一个财年每股收益也为$0。</p>
</div><h2>TuHURA Biosciences Trading Down 5.5%</h2>
<div class="lb-trans"><h2>TuHURA Biosciences 股价下跌 5.5%</h2>
</div><p>TuHURA Biosciences stock opened at $2.40 on Friday. The company has a market capitalization of $152.83 million, a price-to-earnings ratio of -3.81 and a beta of -0.01. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $4.20. The stock's 50 day moving average is $2.05 and its 200-day moving average is $1.60.</p>
<div class="lb-trans"><p>TuHURA Biosciences 的股票在星期五开盘价为$2.40。该公司的市值为 1.5283 亿美元，市盈率为-3.81，贝塔值为-0.01。TuHURA Biosciences 的 12 个月低点为$0.41，12 个月高点为$4.20。该股票的 50 日移动平均线为$2.05，200 日移动平均线为$1.60。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of equities research analysts have recently weighed in on HURA shares. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of TuHURA Biosciences in a report on Tuesday, April 21st. Citigroup started coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued an &#34;outperform&#34; rating on the stock. Citizens Jmp started coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued a &#34;market outperform&#34; rating and a $9.00 price objective for the company. HC Wainwright reissued a &#34;buy&#34; rating and issued a $10.00 price objective on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Finally, Rodman &amp; Renshaw assumed coverage on shares of TuHURA Biosciences in a research report on Wednesday, April 15th. They issued a &#34;buy&#34; rating for the company. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $9.00.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对 HURA 股票发表了看法。Weiss Ratings 在 4 月 21 日（星期二）发布的报告中重新给予 TuHURA Biosciences 股票&#34;卖出（e+）&#34;评级。花旗集团在 4 月 27 日（星期一）的研究报告中开始覆盖 TuHURA Biosciences 股票，并给予&#34;跑赢大盘&#34;评级。Citizens Jmp 在 4 月 27 日（星期一）的研究报告中开始覆盖 TuHURA Biosciences 股票，并给予&#34;市场跑赢&#34;评级，目标价为$9.00。HC Wainwright 在 2 月 3 日（星期二）重新给予&#34;买入&#34;评级，并设定目标价为$10.00。最后，Rodman &amp; Renshaw 在 4 月 15 日（星期三）的研究报告中开始覆盖 TuHURA Biosciences 股票，并给予&#34;买入&#34;评级。五位投资分析师对该股票给予买入评级，一位分析师给予卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为&#34;适度买入&#34;，平均目标价为$9.00。</p>
</div><p><strong>Check Out Our Latest Analysis on TuHURA Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我们对 TuHURA Biosciences 的最新分析</strong></p>
</div><h2>Hedge Funds Weigh In On TuHURA Biosciences</h2>
<div class="lb-trans"><h2>对 TuHURA Biosciences 的对冲基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of TuHURA Biosciences in the third quarter worth $26,000. JPMorgan Chase &amp; Co. bought a new position in TuHURA Biosciences during the 2nd quarter worth $27,000. Invesco Ltd. bought a new position in TuHURA Biosciences during the 2nd quarter worth approximately $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of TuHURA Biosciences during the second quarter worth $31,000. Finally, Bank of America Corp DE bought a new position in TuHURA Biosciences during the fourth quarter worth $59,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近增加或减少了对该公司的持股。Virtu Financial LLC 在第三季度购买了 TuHURA Biosciences 的新股份，价值$26,000。摩根大通在第二季度购买了 TuHURA Biosciences 的新头寸，价值$27,000。Invesco Ltd.在第二季度购买了 TuHURA Biosciences 的新头寸，价值约$30,000。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第二季度收购了 TuHURA Biosciences 的新股份，价值$31,000。最后，美国银行在第四季度购买了 TuHURA Biosciences 的新头寸，价值$59,000。目前，机构投资者和对冲基金持有该股票的 0.62%。</p>
</div><h2>TuHURA Biosciences Company Profile</h2>
<div class="lb-trans"><h2>TuHURA Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company's core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.</p>
<div class="lb-trans"><p>TuHURA Biosciences 是一家临床阶段的生物技术公司，专注于利用高维蛋白质组学发现和开发新型治疗药物。公司的核心使命是将复杂的蛋白质特征转化为可操作的药物靶点，涵盖多种疾病领域。通过将蛋白质组数据与先进的计算分析相结合，TuHURA 旨在弥合分子疾病理解与首创疗法开发之间的差距。</p>
</div><p>At the heart of TuHURA's approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.</p>
<div class="lb-trans"><p>TuHURA 的方法的核心是其专有平台，该平台利用多重蛋白质分析生成丰富的疾病状态表型图。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than TuHURA Biosciences</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 TuHURA Biosciences</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVSQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=HURA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in TuHURA Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 TuHURA Biosciences 吗？</h2>
</div><p>Before you consider TuHURA Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 TuHURA Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 TuHURA Biosciences 并不在名单上。</p>
</div><p>While TuHURA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 TuHURA Biosciences 目前在分析师中获得&#34;适度买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

TuHURA Biosciences (HURA) 预计将在周五发布财报